{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=81",
    "query": {
      "intervention": "cohort 2",
      "page": 81
    },
    "page_size": 10
  },
  "pagination": {
    "page": 81,
    "page_size": 10,
    "total_count": 7396,
    "total_pages": 740,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=82&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=80&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T14:01:19.363Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06310304",
      "title": "A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib IR",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-03-26",
      "completion_date": "2024-05-15",
      "has_results": false,
      "last_update_posted_date": "2024-06-05",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06310304"
    },
    {
      "nct_id": "NCT05973084",
      "title": "COVID-19 Transmission and Morbidity in Malawi",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SARS CoV 2 Infection",
        "SARS CoV 2 Vaccination"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "5 Years to 75 Years"
      },
      "enrollment_count": 1500,
      "start_date": "2023-01-17",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05973084"
    },
    {
      "nct_id": "NCT04590781",
      "title": "Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma",
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "XmAb18087",
          "type": "BIOLOGICAL"
        },
        {
          "name": "XmAb18087 ± Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-05-10",
      "completion_date": "2022-03-24",
      "has_results": true,
      "last_update_posted_date": "2023-04-20",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Los Angeles, California • Lebanon, New Hampshire + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04590781"
    },
    {
      "nct_id": "NCT00347919",
      "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Breast"
      ],
      "interventions": [
        {
          "name": "pazopanib (GW786034) 400 mg",
          "type": "DRUG"
        },
        {
          "name": "lapatinib (GW572016) 1500 mg",
          "type": "DRUG"
        },
        {
          "name": "lapatinib (GW572016) 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "pazopanib (GW786034) 800 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 189,
      "start_date": "2006-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-02-25",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 19,
      "location_summary": "Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00347919"
    },
    {
      "nct_id": "NCT03222492",
      "title": "Brentuximab Vedotin for Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis",
        "Scleroderma",
        "dcSSc"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2017-09-20",
      "completion_date": "2023-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222492"
    },
    {
      "nct_id": "NCT01243892",
      "title": "A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "NuSpin",
          "type": "DEVICE"
        },
        {
          "name": "Somatropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "2 Years to 14 Years"
      },
      "enrollment_count": 18,
      "start_date": "2010-11",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2016-12-01",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01243892"
    },
    {
      "nct_id": "NCT02734199",
      "title": "HER Salt Lake Initiative",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Birth Control",
        "Contraception"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 45 Years · Female only"
      },
      "enrollment_count": 4430,
      "start_date": "2014-11",
      "completion_date": "2020-03",
      "has_results": false,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02734199"
    },
    {
      "nct_id": "NCT06516887",
      "title": "Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lung Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "bemcentinib",
          "type": "DRUG"
        },
        {
          "name": "pacritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2024-12-27",
      "completion_date": "2026-05-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06516887"
    },
    {
      "nct_id": "NCT03078400",
      "title": "Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "SPL-108",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Splash Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 14,
      "start_date": "2017-03-10",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey • New York, New York",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078400"
    },
    {
      "nct_id": "NCT06774144",
      "title": "Rezafungin Prophylaxis in Liver Transplant",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Liver Transplant Infection",
        "Fungal Infection"
      ],
      "interventions": [
        {
          "name": "Rezafungin",
          "type": "DRUG"
        },
        {
          "name": "Standard of care antifungal prophylaxis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fernanda P Silveira, MD, MS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 385,
      "start_date": "2025-10-15",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-20T14:01:19.363Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06774144"
    }
  ]
}